A Critical Review of Phyiotherapy Editor’s Comments on Statistical Practice

Matthew Tenan1 & Aaron R. Caldwell2

1 Rockefeller Neuroscience Institute, West Virginia University, Morgantown, West Viriginia, USA

2 Natick, MA

PREPRINT: NOT PEER REVIEWED

The authors made the following contributions. Matthew Tenan: Conceptualization, Writing - Original Draft Preparation, Writing - Review & Editing; Aaron R. Caldwell: Writing - Original Draft Preparation, Writing - Review & Editing.

**Corresponding Author:** Matthew Tenan, West Viginia University. E-mail: [matthew.tenan@hsc.wvu.edu](mailto:matthew.tenan@hsc.wvu.edu)

**Keywords:** Statistics, Physiotherapy, Estimation, Significance, Confidence Interval

Abstract

Recently, a group of editors from physiotherapy jouranls wrote a joint editorial on the use of statistics in their journals. Like many editorials before them, the editors, who were not statistical experts themselves, put forth numerous recommendations to physiotherapy researchers on how to analyze and report their statistical analyses. This editorial unfortunately suffers from numerous mischaracterizations or outright falsehoods regarding statistics. After a thorough review, two major issues appear throughout the editorial. First, the editors incorrectly state that the use of confidence intervals (CI) would alleviate some of the issues with significance testing. Second, the editors incorrectly assume “smallest worthwhile change” statistics are immutable facts related to some ground truth of treatment effects. In this critical review, we briefly outline some of the problematic statements made by the editors and offer some simple alternatives that we believe are statistical sound and easy for the average physiotherapy researcher to implement.

We read with interest the recent Editorial written by [Elkins et al.](#ref-elkins2022) ([2022](#ref-elkins2022)), who are the Editor-in-Chief members of the International Society of Physiotherapy Journal Editors (heretofore referred to as “The Editorial”). We applaud the author group for encouraging clinical researchers to look beyond null-hypothesis significance testing (NHST) and into the realm of effect estimation. In the Frequentist framework, upon which The Editorial ([2022](#ref-elkins2022)) solely describes, NHST and effect estimation are two sides of the same coin with fundamental mathematical relationships, so it makes perfect sense to describe the analyses and results of clinical research to the fullest extent possible. As methodological tutorials have described previously ([Rafi & Greenland, 2020](#ref-rafi2020)), using estimation, or “unconditional,” approach to reporting statistics is entirely valid. However, the Editorial ([2022](#ref-elkins2022)) also contains a multitude of incorrect or misleading statements and the central thesis that Frequentist Confidence Intervals (CIs) should be contrasted against a point estimate of Smallest Worthwhile Effect (SWE) is fundamentally flawed. In this short response, we will briefly detail a non-exhaustive list of misleading statements in the Editorial ([2022](#ref-elkins2022)) and expand on the statistical issues with suggesting that CI overlap with SWE metrics be used instead of NHST.

# 1 Misleading Statements about Statistics

At a foundational level, the goal of NHST is to make inferences with an eye towards error control and the goal of Estimation, whether Frequentist or Bayesian, is to quantify the magnitude of an effect and the certainty of that effect (which is also directly related to error control in a frequentist paradigm). As [Elkins et al.](#ref-elkins2022) ([2022](#ref-elkins2022)) seems to understand (page 2, paragraph 6), there is a mathematical relationship between the p-values calculated through NHST and confidence intervals around model estimates ([Altman & Bland, 2011](#ref-altman2011)). For this reason, it is surprising the number of misstatements made within the Editorial ([2022](#ref-elkins2022)) regarding NHST and CIs. For example, Table 1 in the Editorial ([2022](#ref-elkins2022)) states “Statistically significant findings are not very replicable”; however, if exactly reproducing a study repeatedly in the same population with different samples, one would have the exact same replication characteristics for both p-values and CIs. This would seem to be a misunderstanding of the replication crisis which, while tangentially related to p-values, is largely due to systematic publication practices and the behavior of researchers. The authors also seem to forget that a move to CIs would suffer from these exact same issues and would not magically solve the problem of replicability ([Hoekstra et al., 2014](#ref-hoekstra2014); [Morey et al., 2015](#ref-morey2015)).

Table 1 also makes some very peculiar assumptions about interventions in clinical trials by stating without evidence that “Almost all interventions would be expected to have some effect, even if that effect was trivially small.” It is possible this is inelegant wording, and the intention was to state that, within a given trial, it is highly unlikely for a measured construct to be exactly nil. This appears to be a vague allusion to Lindley’s paradox ([Lindley, 1957](#ref-lindley)) and Bayesian perspective that, given a large enough sample size, NHST will always yield a significant effect ([Rouder et al., 2009](#ref-rouder2009bayesian)). That may be probabilistically true, but that is why NHST testing for group differences is testing at an acceptable alpha level or, in the case of equivalence or non-inferiority testing, looking to determine whether an intervention performs the same as Standard of Care or at least does not perform worse given an acceptable level of error ([Mazzolari et al., 2022](#ref-mazzolari2022)). Moreover, this statement ignores the Neyman-Pearson approach of balancing type 1 and type 2 errors. A statistician trained in the Neyman-Pearson approach would know that the alpha level could be lowered in situations where negligible effects could be detected (thereby balancing the type 1 and type 2 error rates), or secondary equivalence testing could be utilized to prevent small effects from being declared as “significant” when they are practically equivalent ([Campbell & Gustafson, 2018](#ref-campbell2018)).

The related statement in the Editorial ([2022](#ref-elkins2022)) that “All trials should therefore identify an effect” (Table 1), is simply inaccurate and not justifiable in any case that we can envision; though, it is often unclear if the Editorial ([2022](#ref-elkins2022)) is talking about an effect measured by a statistical model/test (which can always be wrong) or a “real” effect which can never be truly known in empirical work. Finally, there is a bit of irony in that while the Editorial ([2022](#ref-elkins2022)) states, “it is possible to put a confidence interval around any statistic, regardless of its use, including mean difference, risk, odds, relative risk, odds ratio, hazard ratio, correlation, proportion, absolute risk reduction, relative risk reduction, number needed to treat, sensitivity, specificity, likelihood ratios, diagnostic odds ratios, and difference in medians.” They omit the fact that SWE or Minimal Clinically Important Difference (MCID) metrics can and should also be reported with confidence intervals. These estimates of “clinical relevance” are subject to the same sampling errors as an estimate of treatment effect.

# 2 Smallest Worthwhile Effect and Minimal Clinically Important Difference Values are Flawed

A failure to recognize the empirical ambiguity in the SWE/MCID metric is a fatal flaw in the Editorial ([2022](#ref-elkins2022)) as the primary thesis and remediation for supposed ills of NHST are to examine the overlap between effect estimates and the SWE/MCID. Many researchers, including one author of this manuscript ([Tenan et al., 2020](#ref-tenan2020)), have noted that there are a multitude of issues with SWE/MCID measures reported in the literature.

* **Potential Issues with MCID**

1. Not all measures have SWE or MCIDs in the literature, something the Editorial ([2022](#ref-elkins2022)) overtly recognizes.
2. There is no consensus, accepted calculation for SWE or MCID metrics. To our count, there are at least nine ways that these have been derived in the literature ([Ferreira, 2018](#ref-ferreira2018)).
3. The vast majority or nearly all SWE/MCID metrics reported in the physiotherapy literature do not meet the criteria for SWE conventions set out in by [Ferreira](#ref-ferreira2018) ([2018](#ref-ferreira2018)), which is the SWE manuscript the Editorial ([2022](#ref-elkins2022)) cites supporting SWE/MCID use.
4. Whether developing a SWE/MCID via [Ferreira](#ref-ferreira2018) ([2018](#ref-ferreira2018)) criteria or the more common ROC analysis anchoring to another scale, such as the Global Rating of Change scale, this requires dichotomizing an interval or continuous scale. This dichotomization is frequently arbitrary and subject to researcher discretion, making it a substantial source of variance between studies creating SWE/MCID metrics. In general, dichotomization should be avoided at all costs in medical research ([Senn, 2005](#ref-senn2005dichotomania)).
5. For a given SWE/MCID, there are often many different anchors reported in the literature, resulting in different SWE/MCID metrics, even for the same population.
6. Many SWE/MCID are likely biased by regression-to-the-mean, as they use change scores without accounting for the baseline measurement ([Tenan et al., 2020](#ref-tenan2020)).
7. A SWE/MCID, itself, is a point estimate based upon work performed in a sample of the population which is theorized to generalize to that population; as such, all SWE/MCID metrics should be reported with and understood to have confidence intervals around the reported point estimates

Point #7 on the list is what we will primarily discuss throughout the rest of this manuscript, though any one of the above listed issues, in isolation, should give the Editor-in-Chiefs’ who composed the Editorial ([2022](#ref-elkins2022)) pause when suggesting that the estimate CI overlap with a SWE/MCID should be used to fully supplant NHST. the Editorial ([2022](#ref-elkins2022)) states “If the estimate and the ends of its confidence interval are all more favorable than the smallest worthwhile effect, then the treatment effect can be interpreted as typically considered worthwhile”; however, this “smallest worthwhile effect” (SWE/MCID) is being treated as some sort of immutable ground-truth. In fact, an empirically derived SWE/MCID is, by its very nature, going to be derived from a sample of the population and thus have confidence intervals around that point estimate. If we ignore points 1-6 on the previous list, and pretend that the only issue with SWE/MCID measures is that they are not immutable ground-truths, but rather another estimate to compare against, do we have a path forward as the Editorial ([2022](#ref-elkins2022)) suggests? Ironically we do, and it is through NHST! If the estimate and the 95% Confidence intervals around both the SWE/MCID and the research study’s effect are reported, then it can be statistically determined if these two estimates are different from each other via the following method articulated by [Altman](#ref-altman2003) ([2003](#ref-altman2003)) where the estimates for the study result is and the SWE/MCID estimate is and their respective standard errors are represented as and .

* **Steps to back calculate significance**

1. Assume that the 95% CIs are parametric in nature and back-calculate the Standard Errors (SE) for each estimate ([Higgins et al., 2019](#ref-cochrane6)) using the upper limit (UL) and lower limit (LL) of the CI.
2. Calculate the difference () in estimates
3. Calculate the Standard Error of the Difference ()
4. Calculate the -score
5. The -score can then be used to test of the null hypothesis that, in the population, the difference, , is zero by referencing the calculated -score against the normal distribution -table found in the back of many statistics textbooks.

# 3 Alternative Hypothesis Tests

The Editorial ([2022](#ref-elkins2022)) sets out to tell researchers that p-values should not be used but the only method which makes their proposed NHST alternative statistically valid is, in fact, a p-value. While the above procedure for assessing differences between a research study estimate and an empirical SWE/MCID certainly could be performed, the list of 7 issues we’ve identified with SWE/MCID metrics leads us to believe that the proposed new method is inferior to current standards of practice in their journals, if it has any face validity at all. If one can detach themselves from the often-misleading statements and flawed suggestion to contrast SWE point estimates with study confidence intervals in the Editorial ([2022](#ref-elkins2022)), the concept that researchers should think more critically about their research questions and analyses is an excellent suggestion. In fact, if we are willing to accept that SWE/MCIDs are not immutable facts but rather “reasonably good thresholds in certain circumstances,” similar to an alpha level of 0.05, there exists a NHST-based framework that seems to approximate the goal of comparing sample a “clinically meaningful bound” against sample population estimates: superiority, equivalence, non-inferiority, and minimal effects hypothesis tests ([Caldwell & Cheuvront, 2019](#ref-caldwell2019); [Mazzolari et al., 2022](#ref-mazzolari2022)). Therefore, many of the goals outlined in the the Editorial ([2022](#ref-elkins2022)) could very well be accomplished with NHST and p-values.

## 3.1 Vignette on Conditional Equivalence Testing

For this vignette we will revisit a study on glucocorticoid steroid injections for knee osteoarthritis ([Deyle et al., 2020](#ref-vigex)), which we believe is an example that physiotherapists will find relevant. In the study ([Deyle et al., 2020](#ref-vigex)), patients with osteoarthritis were assigned to glucocorticoid injections (experimental group; GLU) or physical therapy (concurrent control; CON). The study also used the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 1 year (scores range from 0 to 240). So, in this case, we may want to perform a simple t-test on the mean differences where the null hypothesis is zero *and* perform two one-sided tests (TOST) to test for equivalence. These tests conceptually examine whether the treatment groups are statistically different and whether the treatment groups are statistically ‘the same.’ This type of test can be accomplished in almost any statistical program (e.g., R, SPSS, SAS, jamovi, JASP, or Stata). However, an author of this comment (ARC) has specifically created functions for this purpose in the [TOSTER](https://aaroncaldwell.us/TOSTERpkg) R package and jamovi module.

[Deyle et al.](#ref-vigex) ([2020](#ref-vigex)) state in the article that a difference of 12 units on the WOMAC scale between GLU and CON was considered the SWE and so we can set the equivalence bounds to this value.[[1]](#footnote-1) Some researchers may use some type of SWE/MCID to set the equivalence, but, as we mentioned above, even these empirically derived equivalence bounds are subject to sampling error. There are many subjective and objective methods of setting an equivalence bound ([Lakens et al., 2018](#ref-lakens2018)), and researchers should be careful in describing why and how they set their equivalence bounds.

The results presented by [Deyle et al.](#ref-vigex) ([2020](#ref-vigex)) are clear, and show an estimated treatment effect of 18.8 points 95% C.I.[5.0, 32.6], p = 0.008. From these we can see that that the NHST interpretation, at an alpha level of 0.05, would reject the null hypothesis of zero effect. However, we can also perform an equivalence test, using TOST, with the equivalence bounds set at 12 units. Such an analysis would yield a p-value of approximately 0.83 (p = 0.83). Therefore, we would reject the null hypothesis of no effect, but retain the null of non-equivalence. Essentially, we could conclude there is an effect and the magnitude is non-negligible. From a clinical perspective these statistics would indicate that the use of GLU over CON would likely lead to worse outcomes for osteoarthritis patients. Details on how to perform this analysis can be found in the [appendix](#app1).

# 4 Conclusions

We are sad to see yet another example of scientists making claims about statistics beyond their expertise ([Sainani et al., 2020](#ref-sainani2020)). The unfortunate reality is that authoritative papers such as the Editorial ([2022](#ref-elkins2022)) can do real damage to the field of physiotherapy. First, the incorrect information provided in the Editorial ([2022](#ref-elkins2022)) will undoubtedly mislead physiotherapy researchers towards worse statistical practices and misinformed beliefs about statistics. Second, the Editorial ([2022](#ref-elkins2022)) hurts the reputation of the field of physiotherapy by giving the impression that the field is uninformed and has a poor understanding of the very basic concepts of statistics. Misguided commentaries from editorial boards are nothing new within academic publishing ([Mayo, 2021](#ref-mayo2021)). We would caution all non-statisticians to avoid making such sweeping statements about proper statistical practice, such as those made in the Editorial ([2022](#ref-elkins2022)), without the involvement of a variety of statisticians. Even statisticians have diverse viewpoints on how statistics should be applied to the analysis of data (e.g., Frequentist versus Bayesian schools of thought), and editorial commentaries should not be the place for picking philosophical sides. Instead, editorial commentaries should be focused on improving the reporting of statistics within their journals to ensure whatever analytical approach is used is appropriately reported for public consumption.[[2]](#footnote-2)

# 5 Additional Information

## 5.1 Acknowledgements

We would like to thank Nisha Charkoudian for her critical comments on a early draft of this manuscript. We would also like to thank Andrew Vigotsky for catching a small error in our equations in the first preprint version.

## 5.2 Funding information

No funding was provided for this work.

## 5.3 Data and Supplementary Material Accessibility

There is no data associated with this work.

# 6 Appendix 1: Vignette Analysis with TOSTER

We can then use the tsum\_TOST function within the package to perform the required statistical tests. We should note that both authors would prefer to use an ANCOVA to analyze results from a pre-post study.

library(TOSTER)  
test1 = tsum\_TOST(  
 m1 = 55.8, m2 = 37, # Means  
 sd1 = 53.8, sd2 = 30.7, # SD  
 n1 = 78, n2 = 78, # Sample Sizes  
 hypothesis = "EQU", low\_eqbound = -12, high\_eqbound = 12)  
test1$decision$ttest

## [1] "The null hypothesis test was significant, t(122.34) = 2.680, p = 8.37e-03"

test1$decision$TOST


## [1] "The equivalence test was non-significant, t(122.34) = 0.970, p = 8.33e-01"

test1$decision$combined

## [1] "NHST: reject null significance hypothesis that the effect is equal to zero \nTOST: don't reject null equivalence hypothesis"

We can also provide a plot of the estimates with multiple confidence intervals.

plot(test1)



*Figure* *1.*  A visualization of the cumulative distribution function with 4 levels of confidence being displayed for the standardized mean difference (top panel) and the mean difference (bottom panel)

The interpretation provided above takes a Neyman-Pearson perspective. Both the NHST and TOST tests have an alpha-level of 0.05 and one reached significance will the other did not. Therefore, an author using this approach would have to conclude that one null hypothesis is rejected regarding GLU while other other null hypothesis is rejected.

However, those who wish to use an estimation approach may have a different interpretation. Under the approach outlined by [Rafi & Greenland](#ref-rafi2020) ([2020](#ref-rafi2020)), we could instead look at the data and see how “compatible” the data is with each competing hypothesis (i.e., NHST versus TOST). From this perspective, the interpretation is much more fluid, and one could conclude that the data is more incompatible with “no effect” than “equivalence” (p-values of 0.008 and 0.83, respectively).

Both perspectives are valid and it is up to researchers to decide how they plan to tests or estimate their effects. Researchers should be consistent with whatever language (e.g., estimation or NHST) they use within each study.

# References

Altman, D. G. (2003). Statistics notes: Interaction revisited: The difference between two estimates. *BMJ*, *326*(7382), 219–219. <https://doi.org/10.1136/bmj.326.7382.219>

Altman, D. G., & Bland, J. M. (2011). How to obtain the confidence interval from a p value. *BMJ*, *343*(aug08 1), d2090–d2090. <https://doi.org/10.1136/bmj.d2090>

Caldwell, A. R., & Cheuvront, S. N. (2019). Basic statistical considerations for physiology: The journal temperature toolbox. *Temperature*, *6*(3), 181–210. <https://doi.org/10.1080/23328940.2019.1624131>

Campbell, H., & Gustafson, P. (2018). Conditional equivalence testing: An alternative remedy for publication bias. *PLOS ONE*, *13*(4), e0195145. <https://doi.org/10.1371/journal.pone.0195145>

Deyle, G. D., Allen, C. S., Allison, S. C., Gill, N. W., Hando, B. R., Petersen, E. J., Dusenberry, D. I., & Rhon, D. I. (2020). Physical therapy versus glucocorticoid injection for osteoarthritis of the knee. *New England Journal of Medicine*, *382*(15), 1420–1429. <https://doi.org/10.1056/NEJMoa1905877>

Elkins, M. R., Pinto, R. Z., Verhagen, A., Grygorowicz, M., Söderlund, A., Guemann, M., Gómez-Conesa, A., Blanton, S., Brismée, J.-M., Ardern, C., Agarwal, S., Jette, A., Karstens, S., Harms, M., Verheyden, G., & Sheikh, U. (2022). Statistical inference through estimation: Recommendations from the international society of physiotherapy journal editors. *Journal of Physiotherapy*, *68*(1), 1–4. <https://doi.org/10.1016/j.jphys.2021.12.001>

Ferreira, M. (2018). Research note: The smallest worthwhile effect of a health intervention. *Journal of Physiotherapy*, *64*(4), 272–274. <https://doi.org/10.1016/j.jphys.2018.07.008>

Higgins, J. P., Li, T., & Deeks, J. J. (2019). Choosing effect measures and computing estimates of effect. *Cochrane Handbook for Systematic Reviews of Interventions*, 143–176. <https://training.cochrane.org/handbook/current/chapter-06>

Hoekstra, R., Morey, R. D., Rouder, J. N., & Wagenmakers, E.-J. (2014). Robust misinterpretation of confidence intervals. *Psychonomic Bulletin & Review*, *21*(5), 1157–1164. <https://doi.org/10.3758/s13423-013-0572-3>

Lakens, D., Scheel, A. M., & Isager, P. M. (2018). Equivalence testing for psychological research: A tutorial. *Advances in Methods and Practices in Psychological Science*, *1*(2), 259–269. <https://doi.org/10.1177/2515245918770963>

Lindley, D. V. (1957). A statistical paradox. *Biometrika*, *44*(1-2), 187–192. <https://doi.org/10.1093/biomet/44.1-2.187>

Mayo, D. G. (2021). The statistics wars and intellectual conflicts of interest. *Conservation Biology*. <https://doi.org/10.1111/cobi.13861>

Mazzolari, R., Porcelli, S., Bishop, D. J., & Lakens, D. (2022). Myths and methodologies: The use of equivalence and non-inferiority tests for interventional studies in exercise physiology and sport science. *Experimental Physiology*. <https://doi.org/10.1113/ep090171>

Morey, R. D., Hoekstra, R., Rouder, J. N., Lee, M. D., & Wagenmakers, E.-J. (2015). The fallacy of placing confidence in confidence intervals. *Psychonomic Bulletin & Review*, *23*(1), 103–123. <https://doi.org/10.3758/s13423-015-0947-8>

Rafi, Z., & Greenland, S. (2020). Semantic and cognitive tools to aid statistical science: Replace confidence and significance by compatibility and surprise. *BMC Medical Research Methodology*, *20*(1). <https://doi.org/10.1186/s12874-020-01105-9>

Rouder, J. N., Speckman, P. L., Sun, D., Morey, R. D., & Iverson, G. (2009). Bayesian t tests for accepting and rejecting the null hypothesis. *Psychonomic Bulletin & Review*, *16*(2), 225–237.

Sainani, K. L., Borg, D. N., Caldwell, A. R., Butson, M. L., Tenan, M. S., Vickers, A. J., Vigotsky, A. D., Warmenhoven, J., Nguyen, R., Lohse, K. R., Knight, E. J., & Bargary, N. (2020). Call to increase statistical collaboration in sports science, sport and exercise medicine and sports physiotherapy. *British Journal of Sports Medicine*, *55*(2), 118–122. <https://doi.org/10.1136/bjsports-2020-102607>

Senn, S. (2005). Dichotomania: An obsessive compulsive disorder that is badly affecting the quality of analysis of pharmaceutical trials. *Proceedings of the International Statistical Institute, 55th Session, Sydney*.

Tenan, M. S., Simon, J. E., Robins, R. J., Lee, I., Sheean, A. J., & Dickens, J. F. (2020). Anchored minimal clinically important difference metrics: Considerations for bias and regression to the mean. *Journal of Athletic Training*, *56*(9), 1042–1049. <https://doi.org/10.4085/1062-6050-0368.20>

1. The choice of the equivalence bound is arbitrary and may vary depending on the purpose of the study. [↑](#footnote-ref-1)
2. The publication of didactic papers on statistical practices authored by individuals with formal statistics education, such as the “Statistics Notes” series that the British Medical Journal published 1994-2017, are an invaluable resource, but should not be considered editorial position statements. [↑](#footnote-ref-2)